Diligence memo · auto-generated · as of July 2, 2026
Accelalox Inc.
Accelalox Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Accelalox Inc. operates in Pharmaceuticals, based in MENLO PARK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Accelalox Inc. has raised $430K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $430K on 2008-01-31.
Most recent recorded round closed around 2008-01-31.
Valuation (modeled)modeled
Provath models Accelalox Inc. at approximately $20M (range $241K–$231M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.23× the median modeled value of Pre-Seed Pharmaceuticals companies in 2007–2009 (21 peers) — value vs value, same stage and era. Within the normal band (123% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 18.4 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 11% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 28% of those peers.
Closest niche peers: Entopica Therapeutics, Inc., Pneumoflex Systems Llc, Anterion Therapeutics, Inc., Ikano Therapeutics Inc., Aiko Biotechnology Inc.
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.